Andre Goy, MD, MS

Articles

Dr. Goy on the Efficacy of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

March 10th 2021

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Dr. Goy on the Utility of NGS in Identifying Aggressive MCL Subtypes

October 1st 2020

Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.

Dr. Goy on the Evolution of Treatment Selection in MCL

May 13th 2020

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Dr. Goy on the Evolution of Treatment Selection in MCL

May 12th 2020

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Dr. Goy on Research Efforts With BTK Inhibitors in MCL

May 12th 2020

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Dr. Goy on Research Efforts With BTK Inhibitors in MCL

May 11th 2020

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Dr. Goy on Comparing the Toxicity Profiles of BTK Inhibitors in MCL

May 8th 2020

Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.

Dr. Goy on the Progression of MCL Treatment

April 8th 2020

Andre Goy, MD, MS, discusses the paradigm shift in the treatment of patients with mantle cell lymphoma that has occurred over the past decade.

Dr. Goy on Combinations With Novel Agents in Relapsed/Refractory MCL

February 14th 2020

Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Goy the Evolution of Treatment in Relapsed/Refractory MCL

February 11th 2020

Andre Goy, MD, MS, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma.

Dr. Goy on the Results of the FLYER Trial in DLBCL

January 8th 2020

Andre Goy, MD, MS, chief, discusses the results of the multicenter FLYER trial in patients with diffuse large B-cell lymphoma.

Dr. Goy on Treating Older Patients With MCL

December 5th 2019

Andre Goy, MD, MS, discusses treatment approaches for older patients with mantle cell lymphoma.

Dr. Goy on the Significance of Becoming an NCI-Designated Cancer Center

May 15th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the significance of becoming a National Cancer Institute-designated cancer center.

Dr. Goy on Treatment Considerations in MCL

April 18th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment considerations in mantle cell lymphoma.

Dr. Goy on Treatment Options for Patients With MCL

April 11th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment options for patients with mantle cell lymphoma (MCL).

Dr. Goy on Future Treatment Approaches in MCL

April 1st 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses future treatment approaches in patients with mantle cell lymphoma.

Dr. Goy on Molecular Features of Mantle Cell Lymphoma

March 15th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the molecular features of mantle cell lymphoma (MCL).

Dr. Goy Discusses Challenges in Treatment of MCL

March 6th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses challenges in the treatment of patients with mantle cell lymphoma.

Dr. Goy Discusses the Cost of CAR T-Cell Therapy

January 12th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the cost of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Goy Discusses the Rituximab Biosimilar FDA Approval

November 29th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the FDA approval of the rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy.